Acupuncture and Moxibustion Enter the Prediabetes Conversation
Prediabetes sits in an awkward clinical middle ground: common, often silent, and far more dangerous than its label suggests. The condition marks a metabolic transition between normoglycemia and type 2 diabetes mellitus, yet screening itself remains inconsistent because fasting glucose, HbA1c, and postprandial glucose do not always classify the same person in the same way. Inter-ethnic variation adds another layer of uncertainty, making the diagnosis as much a problem of biology as of thresholds.
Against that backdrop, acupuncture and moxibustion have moved from traditional practice toward a mechanistically plausible adjunctive approach. The review frames these interventions not as replacements for diet, exercise, or standard metabolic care, but as multimodal therapies aimed at the neuroendocrine and inflammatory circuits that drive glucose dysregulation. In a syndrome built on early insulin resistance, β-cell stress, and organ-level metabolic crosstalk, that kind of broad physiological targeting is not trivial.
Prediabetes is not a single defect. Hepatic insulin resistance tends to dominate impaired fasting glucose, while skeletal muscle insulin resistance is more prominent in impaired glucose tolerance, and both can coexist with β-cell dysfunction. Chronic low-grade inflammation, mitochondrial dysfunction, and lipotoxicity deepen the metabolic injury, creating a cycle in which glucose excursions reinforce further metabolic instability. Any therapy that can interrupt several nodes in that network deserves careful scrutiny.
Metabolic Targets Extend Beyond Glucose Alone
The strongest clinical argument for acupuncture-related therapy lies in its reported ability to improve glycemic parameters while also influencing insulin sensitivity and β-cell homeostasis. Across randomized controlled trials and meta-analytic evidence summarized in the review, acupuncture-related interventions have been associated with reductions in fasting blood glucose, postprandial glucose, and HbA1c, alongside improvements in insulin resistance. Those changes matter because prediabetes is not merely a laboratory state; it is the early physiologic slope toward overt diabetes and its vascular complications.
One sentence captures the clinical stakes plainly: prediabetes is already end-organ biology in motion.
The mechanistic model offered in the review is more ambitious than glucose lowering alone. Acupuncture and moxibustion are described as modulating leptin signaling and restoring β-cell homeostasis through neuroendocrine regulation, including the vago-islet axis and the hypothalamic-pituitary-adrenal axis. If those pathways are modulated in a durable way, the intervention could theoretically soften sympathetic overdrive, improve insulin secretion dynamics, and dampen inflammatory signaling at the same time. For a disorder driven by system-wide metabolic miscommunication, that kind of biological reach is exactly why the field keeps returning to these therapies.
Neuroendocrine Signaling Provides a Plausible Mechanism
The review places unusual emphasis on the biological rationale, and for good reason. Prediabetes reflects not just excess circulating glucose but altered signaling across the liver, muscle, pancreas, adipose tissue, and central nervous system. Acupuncture-related stimulation may influence autonomic balance and hypothalamic pathways that shape insulin secretion, appetite regulation, stress responses, and energy handling. Moxibustion, through thermal stimulation, is also presented as part of a broader regulatory strategy rather than a purely local one.
The vago-islet axis is particularly relevant because vagal activity can influence pancreatic output and metabolic coordination. If neuroendocrine signaling restores more adaptive glucose handling, the downstream effect could be a reduction in the metabolic strain that slowly exhausts β-cell reserve. That biological story fits the clinical observation that early intervention in prediabetes can shift trajectories before irreversible diabetes develops.
Several innovative treatment patterns have been reported as well. Electroacupuncture, Zhuang medicine scraping combined with blood-letting, and auricular acupoint embedding are described as showing promising clinical efficacy and favorable safety profiles. Those modalities differ in technique, but they share a common theme: stimulation of regulatory pathways rather than single-target pharmacology.
Safety and Scalability Make the Therapy Question Harder to Ignore
Safety is part of the appeal. A low-risk intervention with possible metabolic benefit has obvious value in a condition that affects large populations and often remains undertreated until diabetes is established. Unlike medication escalation, acupuncture-based approaches may be easier to integrate into preventive care pathways where patient preference, tolerability, and access shape adherence. The review presents this as a scientifically grounded and scalable option, not a cure-all.
At the bedside, the practical question is not whether acupuncture can fully supplant conventional prevention. It cannot. The more relevant issue is whether it can add measurable metabolic benefit in people who are on the border between stability and progression, especially those who struggle with medication burden or lifestyle adherence. Even modest shifts in fasting glucose or insulin resistance can matter if they delay progression to diabetes.
Evidence Gaps Still Limit Clinical Confidence
Methodological weakness remains the central barrier. The review identifies heterogeneity across studies, small sample sizes, and limited long-term follow-up as persistent problems. Those limitations weaken confidence in the durability of the benefit signal and make it hard to compare one protocol with another. Different acupuncture points, stimulation methods, treatment durations, and adjunctive techniques can all produce a literature that looks positive in aggregate but remains difficult to operationalize in routine care.
A second sentence is worth stating without embellishment: short-term metabolic improvement is not the same as prevention of diabetes.
Standardization is the next obvious need. Large multicenter trials with clearer protocols would help determine whether the observed biochemical changes translate into clinically meaningful prevention of progression from prediabetes to type 2 diabetes mellitus. Multi-omics mechanistic work could also clarify which patients are most likely to benefit and which signaling pathways are actually being modified, rather than presumed.
For now, the review positions acupuncture and moxibustion as adjunctive interventions with plausible biology, encouraging early data, and unresolved methodological weaknesses. The field has moved far enough to justify more rigorous testing, but not far enough to support broad claims beyond the evidence currently available. The most important unanswered question is whether these therapies can produce durable prevention in diverse patient populations under standardized, reproducible conditions.